Fundraising FoxCytoSite BioPharma
Sudbury, US · Founded 2016 · Delaware corporation
Find your way into CytoSite BioPharma
Sign up to see every warm intro you have to CytoSite BioPharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the CytoSite BioPharma team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
EC
Ellen CordoTreasurer
RS
Richard SmithSecretary
JJ
James JensonDirector, President and Chief Executive Officer
Reported raises · per SEC filings
Form D private placements$7.6M disclosed across 4 of 5 rounds · 2017–2020
▶$3MraisedOct 2020 · 12 investors · BiotechnologyRule 506(b)
▶$3MraisedOct 2020 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James JensonExecutive Officer, Director
- Robert GailusDirector
- Mark MintunDirector
- Stephen SandsDirector
- Michel ChuDirector
- Ellen CordoExecutive Officer
- Richard SmithExecutive Officer
- Offering amount
- $5.1M
- Amount sold
- $3M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$4.4MraisedAug 2018 · 13 investors · BiotechnologyRule 506(b)
▶$4.4MraisedAug 2018 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ellen CordoExecutive Officer
- James JensonExecutive Officer, Director
- Michel ChuDirector
- Richard SmithExecutive Officer
- Robert GailusDirector
- Mark MintunDirector
- Offering amount
- $4.4M
- Amount sold
- $4.4M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$125KraisedMay 2018 · 1 investors · BiotechnologyRule 506(b)
▶$125KraisedMay 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Richard SmithExecutive Officer
- Ellen CordoExecutive Officer
- James JensonExecutive Officer, Director
- Offering amount
- $125K
- Amount sold
- $125K
- First sale
- May 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$10.8KraisedDec 2017 · 2 investors · BiotechnologyRule 506(b)
▶$10.8KraisedDec 2017 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ellen CordoExecutive Officer
- Richard SmithExecutive Officer
- James JensonExecutive Officer, Director
- Offering amount
- $10.8K
- Amount sold
- $10.8K
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $264.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- How much funding has CytoSite BioPharma raised?
- CytoSite BioPharma has disclosed $7.6M raised across 4 of its 5 known rounds.
- Where is CytoSite BioPharma headquartered?
- CytoSite BioPharma is headquartered in Sudbury, US.